AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.
FOR more info, visit the PCSO 4D Lotto page.
4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results